Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polyethylene glycol for intestinal inflammation in pediatric cystic fibrosis
2019-004958-29Phase 2Active
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jun 2020
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of macrogol in cystic fibrosis (CF) and inflammatory bowel disease (IBD), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Proportion of patients with low fecal calprotectin at 3 months. Started Jun 2020; status: active.
02
Drugs
macrogol
03
Conditions
cystic fibrosis (CF)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2019-004958-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004958-29.